Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Diagnostic microbiology and infectious disease

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diagmicrobio.2010.05.012PMID 20846586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Community-associated meticillin-resistant Staphylococcus aureus.

  2010cited by this paper
• Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline

  2009cited by this paper
• Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model

  2009cited by this paper
• Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

  2009cited by this paper
• Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

  2009cited by this paper
• Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.

  2009cited by this paper
• Mortality and time to extubation in severe hospital-acquired pneumonia.

  2009cited by this paper
• A Pharmacodynamic Simulation to Assess Tigecycline Efficacy for Hospital-Acquired Pneumonia Compared with Other Common Intravenous Antibiotics

  2008cited by this paper
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

  2008cited by this paper
• Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

  2008cited by this paper
• Investigational treatments for postoperative surgical site infections

  2007cited by this paper
• Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus

  2007cited by this paper
• Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

  2007cited by this paper
• Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

  2007cited by this paper
• Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

  2006cited by this paper
• Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections

  2006cited by this paper
• Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.

  2006cited by this paper
• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005cited by this paper
• The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

  2005cited by this paper
• The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

  2005cited by this paper
• Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.

  2005cited by this paper
• Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

  2005cited by this paper
• Community-associated methicillin-resistant Staphylococcus aureus.

  2005cited by this paper
• Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.

  2004cited by this paper
• Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.

  2004cited by this paper
• Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.

  2003cited by this paper
• Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia

  2003cited by this paper
• International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia.

  2001cited by this paper
• The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group.

  1999cited by this paper
• The SUPPORT Prognostic Model

  1995cited by this paper
• The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments.

  1995cited by this paper
• Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group

  1994cited by this paper
• Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s.

  1991cited by this paper
• Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients.

  1990cited by this paper
• Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

  1990cited by this paper

• INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia

  2025cites this paper
• Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure

  2025cites this paper
• Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations

  2025cites this paper
• Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation

  2025cites this paper
• Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy

  2025cites this paper
• Contemporary antimicrobial treatment rationale of Stenotrophomonas maltophilia infections: a narrative review

  2025cites this paper
• Evaluation of the relative effectiveness of various antibiotic regimens used to treat hospital-acquired pneumonia induced by drug-resistant Acinetobacter baumannii.

  2025cites this paper
• The effects of empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: A systematic review and network meta-analysis of randomized controlled trials.

  2024cites this paper
• Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

  2024cites this paper
• Redirecting pantoprazole as a metallo-beta-lactamase inhibitor in carbapenem-resistant Klebsiella pneumoniae

  2024cites this paper
• Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

  2024cites this paper
• Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections

  2024cites this paper
• Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa

  2024cites this paper
• Carbapenem-resistant Acinetobacter baumannii infections among diabetic and non-diabetic patients and possible effective combination treatments

  2024cites this paper
• Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients

  2024cites this paper
• Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice

  2024cites this paper
• Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence

  2024cites this paper
• Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model

  2024cites this paper
• Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

  2024cites this paper
• Carbapenem vs. non-carbapenem antibiotics for ventilator-associated pneumonia: A systematic review with meta-analysis.

  2024cites this paper
• Molecular Profiling of a Multi-Strain Hypervirulent Klebsiella pneumoniae Infection Within a Single Patient

  2023cites this paper
• Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling

  2023cites this paper
• Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study

  2023influential citation
• Tétracyclines

  2023cites this paper
• Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

  2023cites this paper
• Controversies over the management of infections caused by Amp-C- and ESBL-producing Enterobacterales: what questions remain for future studies?

  2022cites this paper
• Current treatment of nosocomial pneumonia and ventilator-associated pneumonia

  2022cites this paper
• Effect of ICU quality control indicators on VAP incidence rate and mortality: a retrospective study of 1267 hospitals in China

  2022cites this paper
• Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014–2019

  2022cites this paper
• Effect of ICU quality control indicators on VAP incidence and mortality: a Retrospective Study of 1267 hospitals in China

  2022cites this paper
• Infections Due to Acinetobacter baumannii-calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options.

  2022cites this paper
• The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

  2022cites this paper
• Carbapenem-Resistant Enterobacteriaceae: A Retrospective Review of Presentation, Treatment, and Clinical Outcomes in a Tertiary Care Referral Hospital

  2022cites this paper
• DDDT_A_365512 1885..1896

  2022cites this paper
• Outbreak of NDM-1-Producing Escherichia coli in a Coronavirus Disease 2019 Intensive Care Unit in a Mexican Tertiary Care Center

  2022cites this paper
• Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

  2022cites this paper
• Population Pharmacokinetics of Tigecycline: A Systematic Review

  2022cites this paper
• Mortality and clinical cure rates for pneumonia: A systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments.

  2022cites this paper
• Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

  2021cites this paper
• Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019

  2021cites this paper
• Nosocomial Infection.

  2021cites this paper
• Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A. baumannii in Cancer Patient

  2021cites this paper
• Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

  2021cites this paper
• Dose optimization based on pharmacokinetic/pharmacodynamic target of tigecycline.

  2021cites this paper
• Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation

  2021cites this paper
• Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia

  2021cites this paper
• INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care—study protocol for a multicentre randomised controlled trial

  2021cites this paper
• Ceftazidime-avibactam Versus Tigecycline for the Treatment of Carbapenem-resistant Klebsiella Pneumoniae-induced Pneumonia in Critically Ill Patients

  2021cites this paper
• Air pollution and child health: the impact of brick kiln pollution on children's cognitive abilities and physical health in Pakistan

  2021cites this paper
• Tetracyclines

  2021cites this paper
• Intrapulmonary Pharmacokinetics of high doses of tigecycline in patients with Ventilator-Associated Pneumonia (VAP).

  2021cites this paper
• A retrospective study on risk factors and disease burden for hospital-acquired pneumonia caused by multi-drug-resistant bacteria in patients with intracranial cerebral hemorrhage

  2021cites this paper
• Bactericidal and Bacteriostatic Antibiotics

  2021cites this paper
• Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases

  2021cites this paper
• European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine).

  2021cites this paper
• Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia: A Systematic Review and Meta-Analysis.

  2020cites this paper
• Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study

  2020cites this paper
• [Off label uses of tigecycline].

  2020cites this paper
• Is it time to move away from polymyxins?: evidence and alternatives

  2020cites this paper
• Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults

  2020cites this paper
• Risk factors for tigecycline‐induced hypofibrinogenaemia

  2020cites this paper
• Limitations of Registration Trials for Nosocomial Pneumonia.

  2020cites this paper
• Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia.

  2020cites this paper
• ERKRANKUNGEN DER ATMUNGSORGANE

  2020cites this paper
• Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen

  2020cites this paper
• Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods – ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii

  2020cites this paper
• Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy

  2020cites this paper
• Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia–Septicemia Model in Rats

  2020cites this paper
• Update of the treatment of nosocomial pneumonia in the ICU

  2020cites this paper
• Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

  2020cites this paper
• Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections

  2020cites this paper
• Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study

  2019cites this paper
• Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

  2019cites this paper
• Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases

  2019cites this paper
• Mechanisms of Antimicrobial Resistance

  2019cites this paper
• RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

  2019cites this paper
• Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia

  2019cites this paper
• Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models

  2019cites this paper
• Recommendations and guidelines for the treatment of pneumonia in Taiwan.

  2019cites this paper
• Chemical pharmacotherapy for hospital-acquired pneumonia in the elderly

  2019cites this paper
• Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

  2019cites this paper
• Energy consumption and photochemical degradation of Imipenem/Cilastatin antibiotic by process of UVC/ Fe2+/ H2O2 through response surface methodology

  2019cites this paper
• Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.

  2019cites this paper
• Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.

  2019cites this paper
• Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response.

  2019cites this paper
• Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy

  2018cites this paper
• Major publications in the critical care pharmacotherapy literature: January–December 2016

  2018cites this paper
• Busting the Myth of “Static vs Cidal”: A Systemic Literature Review

  2018cites this paper
• Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies

  2018cites this paper
• Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery.

  2018cites this paper
• Entérobactéries productrices de carbapénémases en médecine intensive : thérapeutique

  2018cites this paper
• Knowledge, Adherence and Barriers towards the Prevention of Ventilator Associated Pneumonia among Nurses

  2018cites this paper
• Pharmacodynamic profiling of optimal sulbactam regimens against carbapenem-resistant Acinetobacter baumannii for critically ill patients

  2018cites this paper
• Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia

  2018cites this paper
• The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms

  2018cites this paper
• New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

  2018cites this paper
• The Role of Pharmacometrics in the Development of Antimicrobial Agents

  2018cites this paper
• Preliminary experience with tigecycline treatment for severe infection in children

  2018cites this paper
• Antimicrobial resistance and treatment: an unmet clinical safety need

  2018cites this paper
• Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia

  2018cites this paper